🐻 RVMD $9.7M Bearish Put Structure — Smart Money Bracing for AACR Volatility!

📅 April 10, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just constructed a $9.7M three-legged bearish put structure in Revolution Medicines (RVMD) this morning, buying $6.3M in May $90 puts while simultaneously selling $2.2M in May $65 puts and pocketing $1.2M by shorting near-term April $90 puts — all at the same time for a $2.9M net debit. This isn't a panic sell or a random hedge; this is a precisely engineered position designed to profit if RVMD pulls back 7% or more heading into next week's monster AACR conference (April 17-22), where zoldonrasib gets a plenary-session spotlight that could move the stock violently in either direction. Translation: Someone with very deep pockets is betting the AACR data disappoints — or at least wants serious downside protection before the fireworks start.

---

📊 Company Overview

Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company laser-focused on RAS-addicted cancers — one of the most notoriously hard-to-drug targets in oncology:

• Market Cap: $19.1 Billion
• Industry: Biological Products (Precision Oncology)
• Exchange: NASDAQ
• Current Price: ~$96.18 (April 10, 2026)
• 52-Week Range: $32.16 - $124.49
• Primary Business: Developing novel RAS(ON) inhibitors targeting KRAS mutations across pancreatic, lung, and colorectal cancers — a space with virtually no approved targeted therapies. The company's lead drug daraxonrasib is in five simultaneous Phase 3 trials, and zoldonrasib just landed FDA Breakthrough Therapy Designation in January 2026.

---

💰 The Option Flow Breakdown

📊 What Just Happened

The Tape (April 10, 2026 @ 11:54:40):

Open/Close Classification:

• 🔴 May $90 Put (BUY): BTO — Opening new long put position
• 🟢 May $65 Put (SELL): STO — Opening new short put position
• 🟢 April $90 Put (SELL): STO — Opening new short put position

Z-Score: 🔥 EXTREMELY UNUSUAL on all three legs simultaneously — the May $90 put printed at 16x its typical open interest in a single block, the May $65 put hit 104x its existing OI (essentially nobody owned this before today), and the April $90 put came in at 0.87x existing OI.

🤓 What This Actually Means

This is a three-legged engineered position — not a wild bet, but a precisely calibrated structure. Let me break it down:

Leg 1 + Leg 2: Bear Put Spread (May expiry)

• 🔴 BUY $90 Put for $10.20 — costs $6.3M
• 🟢 SELL $65 Put for $3.60 — collects $2.2M
• Net cost of spread: $4.1M debit
• This spread profits if RVMD falls below $90 by May 15 and maxes out at full value if the stock falls below $65
• Maximum spread value: $25 × 7,500 contracts × 100 = $18.75M if stock goes below $65
• Spread risk/reward: Risk $4.1M to make up to $18.75M

Leg 3: Calendar Component (April near-term short)

• 🟢 SELL April 17 $90 Put for $1.90 — collects $1.2M
• This short expires in just 7 days (April 17, the same week as AACR!)
• If RVMD stays above $90 through April 17, this $1.2M is pure premium income
• It also "pays for" a chunk of the longer-dated May $90 put

The Combined Strategy:

• Total gross premium paid: $6.3M
• Total premium collected: $2.2M + $1.2M = $3.4M
• Net debit (actual cost): $2.9M
• What the trader needs to win: RVMD holds above $90 through April 17 OPEX (so the short April put expires worthless), then RVMD breaks below $90 before May 15 expiration

Real talk: This is a calendar + spread hybrid. The trader is essentially saying "RVMD won't crater THIS WEEK during AACR (selling the April $90 put to collect premium), but WILL pull back meaningfully in the weeks after AACR into May expiration." That's a nuanced, sophisticated view — not a panic sell.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

RVMD has been on a wild ride in 2026. The stock plunged roughly 20% in late January when Merck ended acquisition discussions after a $6 billion valuation gap killed the deal — sending shares from the mid-$110s toward the low $90s overnight. Since then, the stock has clawed back to the $95-97 range on the strength of clinical momentum, unanimous analyst Buy ratings, and AACR hype building. The stock remains 22.65% below its 52-week high of $124.49 — a meaningful gap that reflects how much uncertainty surrounds upcoming binary data events.

Key observations:

• 📉 Merck deal collapse scar: The January crash left a technical overhang around $100-$110; rallies have stalled near that zone
• 🔄 Consolidation range: RVMD has been grinding between $90-$100 for roughly 10 weeks — a tight coil ahead of AACR
• 🎢 Binary event ahead: AACR April 17-22 and the looming RASolute 302 Phase 3 data create extreme two-way volatility risk
• 📊 Volume context: Today's option block is massive relative to typical RVMD option activity — this is not a retail trade

Gamma-Based Support & Resistance Analysis

Current Price: $95.64

The gamma exposure map reveals a very interesting picture — and it lines up almost perfectly with where this option trade is structured.

🔵 Support Levels (Put Gamma Below Price):

🔵 The $90 strike has by far the heaviest put gamma concentration — 2.61B total GEX, with put GEX dominating at 2.56B vs just 0.05B call GEX. This is the most significant gamma concentration in the entire landscape. Notice anything? The option trader struck EXACTLY at $90. This is not a coincidence. The $90 level represents a critical structural inflection point where market maker hedging flows would accelerate dramatically if the stock breaks below it.

🟠 Resistance Levels (Call Gamma Above Price):

🟠 The $105 strike shows the strongest call gamma resistance at 1.40B total GEX — this is where rallies are likely to stall. The $100 level is the first meaningful ceiling; breaking above $100 with conviction would open the door toward $105.

Net GEX Bias: Bearish — Total put gamma (6.77B) significantly exceeds total call gamma (4.58B). The overall options market positioning in RVMD is tilted bearish, consistent with what we're seeing in today's trade.

What this means for traders: RVMD is sitting in a precarious gamma zone. The stock is hovering just 0.67% above the $95 immediate support and 5.89% above the massive $90 gamma wall. If AACR data disappoints and the stock cracks $95, the next stop with meaningful gamma support is $90 — exactly where today's put structure is positioned. Below $90, the next gamma floor is $85 and then $80.

Implied Move Analysis

Options market expected moves as of April 10, 2026:

💥 This is a massive implied move for a 7-day window. The options market is pricing in a nearly ±$8.33 move (±8.75%) by next Friday's April 17 expiration — which is the SAME day as the start of AACR. For context, that lower bound of $86.85 is comfortably below the $90 put that the trader is long. The upper bound of $103.51 aligns neatly with the $100 gamma resistance level identified above.

Translation for regular folks: The options market is essentially screaming that RVMD could trade anywhere from $86.85 to $103.51 by next Friday. The AACR presentations — especially the zoldonrasib plenary slot on April 19 — are the reason for this enormous uncertainty premium.

Key insight: The trader selling the April $90 put is essentially betting the stock STAYS above $86.85 through next Friday's OPEX. They're collecting $1.2M in premium for taking on that risk. If they're right and the April put expires worthless, their net cost on the entire structure drops to just $1.7M. Then the May $90-$65 bear put spread kicks in and they have six more weeks to be right on the downside.

---

🎪 Catalysts

🔥 Imminent Catalysts (Next 7-14 Days)

AACR Annual Meeting — April 17-22, 2026 (STARTS NEXT WEEK!) 🧬

This is THE catalyst that explains today's trade. Revolution Medicines will present nine oral and poster presentations at AACR in San Diego. The key ones:

• 🏆 April 19: Zoldonrasib Phase 1 data in KRAS G12D NSCLC — Plenary "New Frontiers in Precision Oncology" session. A plenary slot at AACR is the scientific equivalent of being the keynote speaker at the biggest conference in your industry. Prior data showed 61% ORR and 89% DCR. Updates with more patients and longer follow-up will be market-moving.
• 📊 April 21 @ 4:05 PM PST: Daraxonrasib + chemotherapy in 1L metastatic PDAC — Late-breaking mini-symposium. Updated combination data ahead of the RASolute 303 Phase 3 trial.
• 📋 Additional daraxonrasib monotherapy data in 1L PDAC with updated response and survival numbers.

Why today's option structure makes sense in this context: The trader sold the April 17 $90 put that expires the SAME DAY AACR starts — betting that even if there's pre-AACR jitters, the stock won't crash below $90 before the data actually hits. Then the May $90-$65 spread profits if post-AACR reality disappoints the hype.

April 17 OPEX — Same Day as AACR Begins 📅

Monthly options expiration falls on April 17 — the opening day of AACR. With the implied move at ±8.75%, expect heightened volatility as short-dated options sellers and buyers scramble.

📅 Near-Term Catalysts (Next 1-3 Months)

RASolute 302 Pivotal Data Readout (H1 2026) — THE BIG ONE 💊

The Phase 3 registrational trial of daraxonrasib in second-line metastatic pancreatic cancer has completed global enrollment. This is widely regarded as the single most important catalyst for RVMD in 2026 — and one of the most anticipated binary events in biotech. A positive OS readout could send the stock toward analyst targets of $120-$170. A failure would be devastating. The data could come as early as Q2 2026 — potentially before or during the May 15 expiration of today's option structure.

Q1 2026 Earnings (May 6-11, 2026) 💰

RVMD is expected to report Q1 2026 results around May 6-11. With 2026 operating expenses guided at $1.6-1.7B and a cash position of $2.0B as of year-end 2025, the burn rate update and enrollment progress across five Phase 3 trials will be closely watched. Q1 earnings fall within the May 15 option expiration window — adding another potential vol catalyst to the May spread position.

📖 Recent Past Catalysts

Merck Acquisition Talks Collapse (Late January 2026) 📉

Merck ended acquisition discussions after failing to agree on valuation — reports cited a $6 billion disconnect between the parties. RVMD plunged ~20% overnight. Reports also surfaced that AbbVie was among interested acquirers. Management's refusal to sell signals pipeline confidence but removes the M&A floor.

FDA Breakthrough Therapy Designation for Zoldonrasib (January 8, 2026) 🏆

The FDA granted Breakthrough Therapy Designation to zoldonrasib for previously treated KRAS G12D NSCLC. Clinical data: 61% ORR, 89% DCR, 1.4-month median time to response, no Grade 4/5 TRAEs. This was RVMD's third BTD — a remarkable regulatory track record for a pre-revenue company.

RASolute 303 Phase 3 Trial Initiated (April 2, 2026) 🚀

Just 8 days ago, Revolution Medicines began treating patients in RASolute 303, a global Phase 3 trial of daraxonrasib in first-line metastatic PDAC. This expands the program from 2L into 1L — a far larger addressable patient population.

Q4 & Full Year 2025 Results (February 25, 2026) 📊

Q4 2025 results showed a $364.9M quarterly net loss and $1.1B full-year loss as the company aggressively funds eight Phase 3 programs. Cash position: $2.0B including the first $250M tranche from the Royalty Pharma $2B funding agreement, providing multi-year runway through potential commercialization.

---

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, and the current catalyst environment, here's how the board is set up:

🐻 Bear Case — "The Disappointment Trade" (Trader's thesis)

• Target: Below $90 by May 15
• Trigger: AACR data underwhelms vs elevated expectations, OR RASolute 302 readout disappoints, OR broader biotech selloff
• Gamma support at $90: Massive 2.61B total GEX — this level will NOT break easily, but once it goes, momentum could accelerate toward $85 (next support)
• Probability (market-implied): The 8.75% weekly implied move puts the lower bound at $86.85 — the market is assigning real probability to a sub-$90 outcome within 7 days
• If below $65 at May expiry: Spread reaches maximum profit of $18.75M gross ($15.85M net of the $2.9M debit)

⚖️ Base Case — "AACR Data Mixed, Stock Consolidates"

• Range: $88-$100 through May expiration
• If stock is between $65-$90 at May 15 expiry: Bear put spread is in-the-money and profitable, with value proportional to how far below $90 the stock settles
• Breakeven for the spread component: $90 - ($4.1M / 750,000 shares) = approximately $84.53 for the bear put spread alone; incorporating the April short put credit, the combined breakeven is approximately $88.13
• Gamma gravity: The $90 level with heaviest put gamma will act like a magnet — expect repeated tests of this level

🚀 Bull Case — "AACR Blows Everyone Away"

• Target: $100-$105 on a zoldonrasib plenary home run
• $100 resistance: First major gamma ceiling per GEX data
• $105 resistance: Strongest resistance zone (1.40B total GEX) — this is where a AACR-driven rally would likely stall
• If stock stays above $90 at May 15 expiry: The bear put spread expires worthless; trader's loss is capped at their $2.9M net debit (since the April short put already expired)
• For bulls: Analyst price targets range from $120 (Piper Sandler) to $170 (Stifel) — but those assume positive pivotal data, not just AACR

---

💡 Trading Ideas

🛡️ Conservative — "The AACR Survivor"

Strategy: Buy the May $85 put outright as a defined-risk bearish bet, spending ~$6-7 per contract (estimate based on current vol environment).

Why this works: You're positioned below both the $90 gamma wall and the implied move lower bound of $86.85. If AACR disappoints and the stock cracks $90, momentum could carry it to $85. Maximum loss is the premium paid — no surprises.

Best for: Traders who want directional bearish exposure with a defined, limited risk and no complex multi-leg management. Set it and let the data work.

Probability of success: Requires roughly an 11-12% decline from current levels — meaningful but within the implied move range for May expiration.

⚠️ Risk: AACR data could be transformative and send the stock to $105+. You lose the premium paid.

---

⚖️ Balanced — "The Calendar Mimic"

Strategy: Replicate the simpler core of today's whale trade — buy the May $90 put and sell the April $90 put (the calendar portion only), spending the net debit (~$8.30 based on $10.20 - $1.90).

Why this works: You collect the inflated AACR premium in the April short put (high IV = fatter premium), let it expire worthless if the stock holds above $90 next week, then own the May $90 put "on the cheap" heading into the RASolute 302 readout and Q1 earnings. You're using the AACR event to fund your post-AACR put.

Best for: Traders with some multi-leg experience who understand calendar spreads. Requires monitoring as April expiry approaches.

Key risk: If RVMD crashes below $90 BEFORE April 17 expiry, the short April put loses money rapidly (you're short gamma into a down move). Size carefully.

---

🚀 Aggressive — "YOLO with Structure"

Strategy: Buy a small number of May $90 puts outright (no spread, no calendar), accepting the full $10.20 cost per share.

Why this works: Maximum leverage to the downside. If the RASolute 302 data drops before May 15 and it's bad news, $90 puts could be worth $20-30 per contract. You own unlimited downside below $90 with no cap on profit (unlike the spread that maxes at $25 move).

Best for: Aggressive traders with high conviction on a negative catalyst AND who can afford to lose 100% of the premium. This is a binary event bet.

Reality check: At $10.20 per contract, you're paying nearly 11% of the stock price for this protection. If RVMD stays above $90 through May 15, the entire premium evaporates. The stock needs to fall more than 4.4% below $90 (to $85.80) just to break even at expiration.

---

⚠️ Risk Factors

🧬 Binary Clinical Data Risk — The Dominant Factor Everything in this trade hinges on AACR (imminent) and RASolute 302 (H1 2026). These are binary events. Pancreatic cancer trials have historically brutal failure rates — even with Breakthrough Therapy Designation, the path from Phase 1/2 signal to Phase 3 success is not guaranteed. A positive readout could send the stock to $120+, making these puts worthless.

💸 IV Crush After AACR With implied move at ±8.75%, options are EXPENSIVE right now. If AACR data is mixed — not great, not terrible — the stock may barely move but implied volatility collapses ("IV crush"), devastating the value of those May $90 puts even if the stock drifts slightly lower.

💀 Short April $90 Put — Gap Risk The trader sold the April $90 put that expires on AACR opening day. If a pre-AACR leak, abstract update, or broader biotech/market selloff sends RVMD gapping below $90 before April 17, the short put bleeds fast. This is the highest-risk leg of the structure.

📉 Gamma Wall at $90 — Hard to Crack The GEX data shows 2.61B total gamma at $90 — the heaviest concentration in the entire landscape. Market maker hedging flows will create natural buying pressure near this level. The stock breaking $90 cleanly requires a significant catalyst, not just drift.

🔥 Cash Burn Trajectory Full-year 2025 net loss was $1.1B, accelerating from $600M in 2024. 2026 OpEx guidance is $1.6-1.7B. Even with the Royalty Pharma $2B backstop, this is a pre-revenue company burning cash aggressively across eight Phase 3 programs.

📊 Unanimous Buy Ratings Create Sentiment Risk With 21 Buy / 0 Sell analyst ratings and price targets of $120-$170, expectations for positive data are extremely elevated. Even "good but not great" AACR data could disappoint relative to the high bar priced into the stock. That's exactly the kind of situation that generates a sell-the-news reaction.

🌍 Macro Sensitivity Pre-revenue biotechs with $1B+ annual burn rates are highly sensitive to risk-off sentiment. A broader market selloff from macro headwinds (tariff escalation, rate surprises) could pressure RVMD regardless of clinical progress.

---

🎯 The Bottom Line

Real talk: This is one of the most thoughtfully constructed options positions we've seen in RVMD — a three-legged $9.7M gross structure that essentially says "RVMD won't crater THIS week during AACR opening, but will pull back meaningfully before May 15."

The structure is smart because it:

1. Collects near-term AACR premium (short April $90 put) to finance the longer trade
2. Caps the maximum loss at $2.9M net debit regardless of scenario
3. Has maximum profit of $15.85M ($18.75M spread value minus $2.9M cost) if RVMD falls below $65 — nearly a 5.5x return on risk
4. Positions around the single most important gamma level in the entire RVMD options landscape ($90 strike with 2.61B total GEX)

Three scenarios to watch:

✅ If you're already bearish: The $90-$65 May bear put spread structure is cleaner than buying naked puts — it dramatically reduces your cost basis by financing with the $65 short put while still giving you full exposure between $90 and $65. Consider a smaller version if you share the bearish AACR thesis.

👀 If you're watching from the sidelines: Mark your calendar for April 19 (zoldonrasib plenary at AACR) and April 21 (daraxonrasib late-breaking data). Those are the two sessions that will tell you whether this bearish bet is going to pay off. The stock's reaction to these presentations will set the tone through May expiration.

🚀 If you're bullish on RVMD: This institutional put structure is a yellow flag — someone sophisticated is paying serious money for downside protection right before the most important event in the company's history. That doesn't mean they're right (the unanimous analyst Buy consensus and $120-$170 price targets are compelling), but it's a reminder to size your bullish positions accordingly and don't go all-in before AACR. The 8.75% implied move says the options market expects a big swing either way.

Mark your calendars:

• 📅 April 17: Monthly OPEX — Short April $90 put expires (or doesn't...)
• 📅 April 19: Zoldonrasib plenary session at AACR — The moment of truth
• 📅 April 21: Daraxonrasib + chemo late-breaking data
• 📅 May 6-11: Q1 2026 earnings
• 📅 May 15: May options expiration — Spread settles
• 📅 H1 2026: RASolute 302 pivotal OS data — The game-changer

The bottom line on this trade: Someone just paid $2.9M net to bet RVMD's headline catalysts over the next 5 weeks come in below the sky-high expectations. That's a view worth respecting — even if you don't share it.

---

⚠️ Disclaimer: This analysis is for educational and informational purposes only and does not constitute financial advice. Options trading involves substantial risk of loss and is not suitable for all investors. You can lose your entire investment in options positions. Past unusual options activity does not predict future stock performance. Always do your own research and consult a qualified financial advisor before making investment decisions. The unusual options activity described here represents one trader's positioning and may reflect hedging, speculation, or other strategies unrelated to directional stock views.